Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Reflections from our chief clinician: The essential role of our research... February 4, 2022 ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer... September 24, 2026 Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with... June 11, 2026 Woman Suffers Seizure And Dies After Making Fatal Error With Her... May 3, 2019 Load more HOT NEWS Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced... PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... How Fatty Liver Disease Helps Cancer Thrive in the Liver Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,...
